


In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1 (currently amended). A method for the treatment ~~or prevention~~ of a condition associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, wherein said method comprises administering, to a patient in need of such treatment, a compound of formula (I)



wherein R₁ is H or Me;

R₂ is H or alkyl and R₃ is H or Me, or R₂ and R₃ are -CH₂- thereby forming a ring;

n is 0 to 2;

X is CH₂ or O; and

the two benzene rings are each optionally substituted with OH, OMe, halogen, NHCHO, NHSO₂Me, CONH₂, SOMe, OCH₂O or CH₂OH;

and wherein the compound is selected from bufeniodol, denopamine, ~~feneterolol~~, ifenprodil, isoxsuprine, labetalol, medroxalol, mesuprine, nyldrin, protokylol, ractopamine, ritodrine, salmefamol and sulfinalolol.

2 (currently amended). The method according to claim 1, wherein the condition is ~~a chronic degenerative disease such as~~ rheumatoid arthritis, osteoarthritis or osteoporosis.

3 (withdrawn and currently amended). The method according to claim 1, wherein the condition is ~~a chronic demyelinating disease such as~~ multiple sclerosis.

4 (withdrawn and currently amended). The method according to claim 1, wherein the condition is ~~a respiratory disease such as~~ asthma or chronic obstructive pulmonary disease.

5 (withdrawn and currently amended). The method according to claim 1, wherein the condition is ~~an inflammatory bowel disease (IBD) such as~~ ulcerative colitis or Crohn's disease.

6 (withdrawn and currently amended). The method according to claim 1, wherein the condition is ~~a dermatological condition such as~~ psoriasis, scleroderma or atopic dermatitis.

7 (withdrawn and currently amended). The method according to claim 1, wherein the condition is ~~a dental disease such as~~ periodontal disease or gingivitis.

8 (withdrawn). The method according to claim 1, wherein the condition is diabetic nephropathy, lupus nephritis, IgA nephropathy or glomerulonephritis.

9 (withdrawn and currently amended). The method according to claim 1, wherein the condition is systemic lupus ~~erythematosus~~ erythematosus (SLE).

10 (withdrawn). The method according to claim 1, wherein the condition is graft vs host disease.

11 (withdrawn). The method according to claim 1, wherein the condition is a pain condition.

12 (withdrawn and currently amended). The method according to claim 11, wherein the pain condition is ~~chronic pain such as~~ chronic back pain, malignant pain, chronic headache (including migraine and cluster headaches) or arthritic pain).

13 (withdrawn and currently amended). The method according to claim 11, wherein the pain condition is ~~acute pain such as~~ post-operative pain, post-traumatic pain or acute disease-induced pain.


14 (withdrawn). The method according to claim 11, wherein the pain condition is neuropathic pain.

15 (cancelled).

16 (currently amended). The method according to claim 1, wherein the compound is in the form of the enantiomer or diastereomer that has ~~relatively~~ little or no activity at [[the]] an α or β adrenoceptor.

17 (cancelled).

18 (new). A method for the treatment of a condition associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, wherein said method comprises administering, to a patient in need of such treatment, a compound of formula (I)



wherein R_1 is H or Me;

R_2 is H or alkyl and R_3 is H or Me, or R_2 and R_3 are $-CH_2-$ thereby forming a ring;

n is 0 to 2;

X is CH₂ or O; and

the two benzene rings are each optionally substituted with OH, OMe, halogen, NHCHO, NHSO₂Me, CONH₂, SOMe, OCH₂O or CH₂OH;

wherein the compound is selected from bufeniode, denopamine, ifenprodil, isoxsuprine, labetalol, medroxalol, mesuprine, nylidrin, protokylol, ractopamine, ritodrine, salmefamol and sulfinalol;

wherein the compound is in the form of the enantiomer or diastereomer that has little or no activity at an α or β adrenoceptor.